Related Experiment Video

Updated: Sep 5, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

11.9K

Osimertinib-related liver injury with successful osimertinib rechallenge: A case report

Yuan-Ling Cheng1, Wei-Kuo Chang2, Hao Yen3

  • 1Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC.

Thoracic Cancer
|July 6, 2022
PubMed

Insights

Osimertinib can cause liver injury in non-small cell lung cancer patients. This case study shows successful management and rechallenge with osimertinib despite drug-induced liver injury.

Area of Science:

  • Oncology
  • Pharmacology
  • Hepatology

Background:

  • Osimertinib is a targeted therapy for advanced non-small cell lung cancer (NSCLC) with specific epidermal growth factor receptor (EGFR) mutations.
  • While generally well-tolerated, EGFR tyrosine kinase inhibitors (TKIs) like osimertinib can cause asymptomatic aminotransferase elevations.
  • Significant drug-induced liver injury (DILI) from osimertinib is considered infrequent.

Observation:

  • A case of osimertinib-related drug-induced liver injury is presented.
  • The patient experienced liver injury during treatment with osimertinib for advanced NSCLC.
  • This liver injury was successfully managed, allowing for treatment continuation.

Findings:

  • The patient developed significant hepatotoxicity attributed to osimertinib.
  • Successful management of the liver injury was achieved.
  • Osimertinib rechallenge was tolerated by the patient.

Implications:

  • This case highlights the potential for osimertinib-induced liver injury.
  • Successful rechallenge suggests that DILI may not always necessitate permanent discontinuation of osimertinib.
  • Further investigation into managing TKI-related hepatotoxicity is warranted for optimizing cancer treatment.
Keywords:
drug-induced liver injurynon-small cell lung cancerosimertinib

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K